243 related articles for article (PubMed ID: 30642296)
1. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Willemsen S; Boere IA; Schoots IG; Piek JMJ; Hofman LN; Beltman JJ; van Driel WJ; Werner HMJ; Baalbergen A; van Haaften-de Jong AMLD; Dorman M; Haans L; Nedelcu I; Ewing-Graham PC; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4833-4843. PubMed ID: 35552938
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
[TBL] [Abstract][Full Text] [Related]
4. Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer.
Nieuwenhuyzen-de Boer GM; Geraerds AJLM; van der Linden MH; van Doorn HC; Polinder S; van Beekhuizen HJ
JCO Clin Cancer Inform; 2022 Sep; 6():e2200076. PubMed ID: 36198130
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients.
Nieuwenhuyzen-de Boer GM; Aamran H; van den Berg CB; Willemsen S; Piek JMJ; Reesink-Peters N; Maliepaard M; van Doorn HC; Polinder S; van Beekhuizen HJ
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568763
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R; van Meurs HS; Rutten MJ; Naaktgeboren CA; Opmeer BC; Gaarenstroom KN; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HWR; Arts HJG; Zusterzeel PLM; Pijnenborg JMA; van Haaften M; Engelen MJA; Boss EA; Vos MC; Gerestein KG; Schutter EMJ; Kenter GG; Bossuyt PMM; Mol BW; Buist MR
Gynecol Oncol; 2017 Sep; 146(3):449-456. PubMed ID: 28645428
[TBL] [Abstract][Full Text] [Related]
7. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.
Rutten MJ; Gaarenstroom KN; Van Gorp T; van Meurs HS; Arts HJ; Bossuyt PM; Ter Brugge HG; Hermans RH; Opmeer BC; Pijnenborg JM; Schreuder HW; Schutter EM; Spijkerboer AM; Wensveen CW; Zusterzeel P; Mol BW; Kenter GG; Buist MR
BMC Cancer; 2012 Jan; 12():31. PubMed ID: 22264278
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
Cordeiro Vidal G; Babin G; Querleu D; Guyon F
Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
10. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
11. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
[TBL] [Abstract][Full Text] [Related]
12. GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial.
van Soolingen NJ; Smorenburg CH; Hamaker ME; Groen WG; Retèl VP; Lok CAR; van de Poll-Franse LV; Trum JW
Trials; 2020 Feb; 21(1):214. PubMed ID: 32087750
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
15. The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.
Nieuwenhuyzen-de Boer GM; van de Berg NJ; Gao XS; Ewing-Graham PC; van Beekhuizen HJ
J Ovarian Res; 2022 Dec; 15(1):140. PubMed ID: 36581854
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the clinical and histological appearances after treatment of advanced stage ovarian cancer with PlasmaJet® device.
Natarajan P; Martha Schofield A; Elena Vinturache A; Ruthven S; Lane S; Duncan Macdonald R
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():311-315. PubMed ID: 38518485
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
18. Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1521-4. PubMed ID: 27488213
[TBL] [Abstract][Full Text] [Related]
19. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
Liberale G; Pop CF; Polastro L; Kerger J; Moreau M; Chintinne M; Larsimont D; Nogaret JM; Veys I
J Visc Surg; 2020 Apr; 157(2):79-86. PubMed ID: 31837942
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
